📊 CABA Key Takeaways
Investment Thesis
Cabaletta Bio is a pre-revenue biotech company with severe cash burn and negative profitability metrics, losing $125.9M annually with an operating cash outflow of $95.7M. While the company maintains adequate liquidity with $60.2M in cash and a 3.60x current ratio, the burn rate at current levels suggests less than 18 months of runway without additional funding or operational changes. The absence of revenue combined with deteriorating unit economics (negative ROE of -90.3% and ROA of -66.4%) indicates the company remains in early clinical/development stages with substantial execution risk.
CABA Strengths
- Adequate near-term liquidity with $60.2M cash and 3.60x current ratio providing runway for operations
- Conservative balance sheet with zero long-term debt and low leverage (0.00x debt/equity ratio)
- Significant shareholder equity base of $139.5M suggesting prior capital raises and investor backing
CABA Risks
- Pre-revenue company with $125.9M net losses and $95.7M annual operating cash burn indicating unsustainable economics without clinical/commercial success
- Less than 18 months of cash runway at current burn rate, necessitating additional capital raise or dramatic operational improvements
- Early stage biotech with no revenue generation and uncertain path to profitability; high probability of total capital loss if pipeline assets fail in development
Key Metrics to Watch
- Operating cash burn rate and runway to profitability or next funding milestone
- Clinical trial progression and regulatory pathway status for lead candidates
- Quarterly cash position changes and any announcement of financing activities or partnerships
CABA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.60x current ratio provides a solid financial cushion.
CABA Profitability Ratios
CABA vs Healthcare Sector
How Cabaletta Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CABA Balance Sheet & Liquidity
CABA 5-Year Financial Trend
5-Year Trend Summary: Cabaletta Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.65 indicates the company is currently unprofitable.
CABA Growth Metrics (YoY)
CABA Capital Allocation
CABA SEC Filings
Access official SEC EDGAR filings for Cabaletta Bio, Inc. (CIK: 0001759138)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CABA
What is the AI rating for CABA?
Cabaletta Bio, Inc. (CABA) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CABA's key strengths?
Adequate near-term liquidity with $60.2M cash and 3.60x current ratio providing runway for operations. Conservative balance sheet with zero long-term debt and low leverage (0.00x debt/equity ratio).
What are the risks of investing in CABA?
Pre-revenue company with $125.9M net losses and $95.7M annual operating cash burn indicating unsustainable economics without clinical/commercial success. Less than 18 months of cash runway at current burn rate, necessitating additional capital raise or dramatic operational improvements.
What is CABA's revenue and growth?
Cabaletta Bio, Inc. reported revenue of N/A.
Does CABA pay dividends?
Cabaletta Bio, Inc. does not currently pay dividends.
Where can I find CABA SEC filings?
Official SEC filings for Cabaletta Bio, Inc. (CIK: 0001759138) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CABA's EPS?
Cabaletta Bio, Inc. has a diluted EPS of $-1.75.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.